FEV1 values were significantly higher after the TIO add-on therapy to fluticasone propionate/formoterol fumarate

 For patients with asthma-chronic obstructive pulmonary disease overlap (ACO), Tiotropium Bromide (TIO) add-on therapy to fluticasone propionate/formoterol fumarate (FP/FM) results in improved lung function, according to a study published May 23, 2022, in the Journal of Asthma and Allergy.

Yoshihisa Ishiura, M.D., Ph.D., from Kansai Medical University in Japan, and colleagues conducted a 12-week open-label crossover pilot study in 18 male patients with stable ACO to examine the effect of TIO 5 µg/day add-on therapy to FP/FM 500/20 µg/day compared with FP/FM alone. The study included a four-week run-in period and two four-week treatment periods.

All patients were ex-smokers. The researchers found that for forced expiratory volume in one second (FEV1), the mean values were 1.21 ± 0.49, 1.20 ± 0.51, and 1.30 ± 0.48 L after the run-in period, after the FP/FM combination therapy period, and after the TIO add-on therapy to FP/FM period, respectively. After the TIO add-on therapy FP/FM period, FEV1 values were significantly higher than those after the run-in period.

The present findings support the potential for TIO add-on therapy via SMI [Soft Mist inhaler], to be known to generate a high fine-particle fraction, to FP/FM as a therapeutic option for ACO. Further, larger studies are required to define the precise etiology of the clinical efficacy of this combination therapy.

Abstract/Full Text (subscription or payment may be required)